In view of the relevance of ATXN2 for the age-progressive disease hepatosteatosis and SCA2, we used the tissues liver and cerebellum, each collected at ages 6 or 24 weeks (always from 4 Atxn2−/− versus 4 Atxn2+/+ mice). This evidence concerns the gene ATXN2 and glycogen storage disease VI.